- Indicated for Treatment of Moderate to Severe Alzheimer's Disease - DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) and Adamas Pharmaceuticals Inc. (NASDAQ: ADMS ...
Another earlier memantine trial – the Benefit and Efficacy in Severely Demented patients during Treatment with Memantine (M-Best or 9403) study – enrolled participants with moderately severe AD as ...
Association of anticonvulsant prophylaxis in patients with primary and metastatic brain tumors and 1-year overall survival: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from ...
Forest and Merz Announce FDA Approval of NAMENDA XR for the Treatment of Moderate to Severe Dementia of the Alzheimer's Type NEW YORK, Jun 21, 2010 (BUSINESS WIRE ...
Actavis and Adamas Pharmaceuticals Inc announced that the US Food and Drug Administration (US FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine ...
Steven T. DeKosky and Bengt Winblad led this live discussion on how the addition of memantine to the clinician's toolbox will change the management of Alzheimer's disease. Following its FDA approval ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 23 (June 10, 2014), pp. 8649-8654 (6 pages) Ketamine is an NMDA receptor (NMDAR) antagonist that elicits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results